Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Farnesyl diphosphate synthase pseudogene 2 (FDPSP2, TCAG_1641456) is annotated as a pseudogene, meaning it is a DNA sequence that resembles a gene but is generally non-functional and does not encode an active molecule. There is no evidence for any protein product, target activity, associated biological function, or clinical relevance. It is not considered a drug target, nor does it belong to any recognized molecular or functional group. This entry appears to be included for genomic annotation purposes rather than active biomedical research, drug targeting, or therapeutic application. If the goal is to pursue a real target related to "farnesyl diphosphate synthase," the correct entry would be "Farnesyl diphosphate synthase" (FDPS), which is an enzyme and a validated therapeutic target, but FDPSP2 itself is only a pseudogene and not a target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Farnesyl diphosphate synthase pseudogene 2 (FDPSP2).